Biologics
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global biologics market intelligence: Discover regulatory updates, R&D trends, and investment opportunities in biopharmaceuticals.
Showing 1–7 of 7 articles
Quick answer
NovaPharmaNews Biologics hub for FDA covers 7 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review
IPEC Excipient World Biologics Summit 2026: Recap
Clinical Outsourcing Trends 2026: Key Takeaways for Pharma
ReDI 2026: FDA Regulatory Strategies Conference Recap
FDA's REdI Conference 2026: Regulatory Strategies & Insights
EpiBiologics Begins Phase 1 Trial of EPI-326 Bispecific Antibody for EGFR-Driven Cancers
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.